AbbVie reports ‘positive’ results from Measure Up 1, Measure Up 2 Phase 3 trials

AbbVie announced positive results from a new post-hoc analysis from the Measure Up 1 and Measure Up 2 Phase 3 studies. The analysis evaluated the efficacy of upadacitinib (15 mg or 30 mg) in patients with moderate-to-severe atopic dermatitis stratified by the severity of disease in the head and neck region at baseline compared to placebo across 16 weeks.1 In this analysis, several optimal and stringent treatment targets – including the achievement of near complete skin clearance in the head and neck region, near complete skin clearance, no to little itch and minimal or no impact on quality of life, were assessed with the treatment of upadacitinib across patient subgroups. Patients were stratified by no-to-mild, moderate, or severe head and neck involvement. “These data stratify the severity of atopic dermatitis in the head and neck region, which is a part of the body that has significant impact on patients and is challenging to treat,” said Kilian Eyerich, MD, PhD, chair and professor at the Department of Dermatology and Venerology of the University of Freiburg, Germany. “At 16 weeks, RINVOQ showed efficacy in patients with moderate-to-severe atopic dermatitis with various degrees of head and neck involvement, achieving optimal treatment targets with combined measures of EASI 90 and WP-NRS 0/1, along with improvement on the patients’ quality of life measured by DLQI 0/1 in a substantial number of patients.”